BioCryst
Pharmaceuticals BCRX today announced that the National
Institute of Allergy and Infectious Diseases (NIAID) has exercised
an option to conduct the investigational new drug (IND) enabling program
and to submit an IND. This option represents an additional $2.5 million
to BioCryst in order to advance the development of BCX4430
as a treatment for Marburg virus disease. NIAID, part of the National
Institutes of Health, granted an initial award of $5.0 million to
BioCryst in September 2013. The total funding could be up to $22.0
million over five years and advance the program through Phase 1 trials,
if all contract options are exercised.
“With these additional funds, BioCryst will rapidly initiate
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in